Clinical trials: Psoriasis Patients
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
PSOBIOTEQ is a national multicentric prospective non interventional study which aims to constitute a French registry of cutaneous psoriasis patients initiating systemic treatment (excluding acitretin and phototherapy) for…
- Trial name
- PSOBIOTEQ (NCT04841187)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriasis, Psoriasis; Arthritis (Etiology)
The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis
PSODEEP 1 is a descriptive digital interview study where we intend to include at least 900 individuals. Individuals with known psoriasis or known psoriatic arthritis will access the digital interview via a QR code distributed via…
- Conditions
- Psoriasis, Psoriasis; Arthritis (Etiology), Koebner Phenomenon
- Trial name
- PSODEEP1 (NCT05589298)
- Where
- Sweden
- Volunteers
- 3,064 people
- Sponsor
- Skane University Hospital
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Rheumatoid Arthritis, Psoriatic Arthritis
Tapering of Biologics in Inflammatory Arthritis Patients in Remission
Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) are types of inflammatory arthritis. They are disabling conditions caused by inflammation in joints that can lead to pain, stiffness, fatigue and joint damage.
- Trial name
- TAPER (NCT04429776)
- Testing
- Drug level testing with feedback provided, Drug level testing with no feedback provided
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- University of Manchester
Rheumatoid Arthritis, Spondyloarthritis
The NOR-SWITCH Study
The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Ulcerative Colitis
- Trial name
- NOR-SWITCH (NCT02148640)
- Testing
- Innovator infliximab, Biosimilar infliximab
- Where
- 30 sites in Norway
- Volunteers
- 482 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.
- Trial name
- NCT01300052
- Testing
- AN2728 ointment, 2%, Ointment Vehicle
- Where
- 10 sites in United States
- Volunteers
- 68 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Plaque Psoriasis
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
- Trial name
- NCT01875991
- Testing
- Etanercept via Autoinjector A, Etanercept via Autoinjector B
- Where
- 37 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Amgen
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Moderate to Severe Plaque Psoriasis
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT06875934
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Plaque Psoriasis
Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast.
- Trial name
- Itch (NCT03146247)
- Testing
- Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
- Where
- Germany
- Sponsor
- Diamant Thaci
Psoriasis
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic…
- Trial name
- RESPONSE (NCT00096928)
- Where
- 182 sites in United States
- Volunteers
- 1,846 people
- Sponsor
- Genentech, Inc.
Plaque Psoriasis
Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
This study is a randomised, double-blind, placebo-controlled, sequential, ascending single-dose, parallel group study to evaluate safety, tolerability, biological activity, and systemic exposure of COVA322 (tumor necrosis factor…
- Trial name
- NCT02243787
- Testing
- COVA322
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Covagen
Psoriasis
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas'…
- Trial name
- NCT05513014
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Safety and Efficacy of Etanercept in Patients With Psoriasis
The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to traditional DMARDs.
- Trial name
- NCT02258282
- Testing
- Etanercept, Control
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chengdu PLA General Hospital
Psoriasis
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in healthy adults and patients with mild to moderate psoriasis.
- Trial name
- NCT02574091
- Testing
- 1% icotinib hydrochloride cream, 2% icotinib hydrochloride cream
- Where
- New Zealand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Plaque Psoriasis Vulgaris
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- DERMIS (NCT03310320)
- Testing
- AZD0284 oral solution 2.5 mg/mL
- Where
- 4 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.
- Trial name
- NCT00227240
- Where
- 2 sites in Germany
- Volunteers
- 753 people
- Sponsor
- Pfizer
Psoriasis
Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy
This study will evaluate the ability of the vaccine to produce antibodies against herpes zoster virus (shingles) and safety of vaccination with Varicella Zoster Vaccine in patients with moderate to severe psoriasis who will…
- Trial name
- NCT02408159
- Testing
- Varicella Zoster Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Innovaderm Research Inc.
Inflammatory Arthritis, Spondylarthropathies
Assessing Pain by the painDETECT Questionnaire (PDQ)
Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score <13) or a neuropathic pain phenotype group (score ≥13)
- Conditions
- Inflammatory Arthritis, Spondylarthropathies, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- NCT06402396
- Testing
- bDMARDS
- Volunteers
- 7,056 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.